Time to response in patients with ALK plus NSCLC receiving alectinib in the phase II NP28673 and NP28761 studies

被引：0

作者：

Gandhi, L. ^{[1
]}

Gadgeel, S. ^{[2
]}

Shaw, A. ^{[3
]}

Barlesi, F. ^{[4
]}

Crino, L. ^{[5
]}

Yang, J. C-H. ^{[6
,7
]}

Dingemans, A-M. C. ^{[8
]}

Kim, D-W. ^{[9
]}

de Marinis, F. ^{[10
]}

Schulz, M. ^{[11
]}

Liu, S. ^{[11
]}

Fish, S. ^{[11
]}

Kotb, A. ^{[12
]}

Ou, S-H. I. ^{[13
]}

机构：

[1] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA

[2] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA

[3] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA

[4] Aix Marseille Univ, Multidisciplinary Oncol & Therapeut Innovat, Marseille, France

[5] Santa Maria della Misericordia Hosp, Med Oncol, Perugia, Italy

[6] Natl Taiwan Univ Hosp, Grad Inst Oncol, Taipei, Taiwan

[7] Natl Taiwan Univ Hosp, Canc Res Ctr, Taipei, Taiwan

[8] MUMC, Pulmonol, Maastricht, Netherlands

[9] Seoul Natl Univ Hosp, Med Oncol, Seoul, South Korea

[10] European Inst Oncol, Thorac Inst Oncol, Milan, Italy

[11] Genentech Inc, US Med Affairs, 460 Point San Bruno Blvd, San Francisco, CA 94080 USA

[12] F Hoffmann La Roche Ltd, Med Affairs, Basel, Switzerland

[13] Univ Calif Irvine, Med Oncol, Orange, CA 92668 USA

来源：

ANNALS OF ONCOLOGY | 2016年 / 27卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1209PD

引用

页数：1

共 50 条

[1] Pooled mutation analysis for the NP28673 and NP28761 studies of alectinib in ALK plus non-small-cell lung cancer (NSCLC).
Puig, Oscar
Yang, James Chih-Hsin
Ou, Sai-Hong Ignatius
Chiappori, Alberto
Chao, Bo H.
Belani, Chandra Prakash
Spira, Alexander I.
Bearz, Alessandra
Duruisseaux, Michael
Allard, John
Birzele, Fabian
Boisserie, Frederic
Lonngren, Ulrika
Bordogna, Walter
Klass, Daniel M.
Newman, Aaron M.
Zeaiter, Ali Hassan
Shaw, Alice Tsang
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[2] Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies
Gadgeel, Shirish
Shaw, Alice T.
Barlesi, Fabrice
Crino, Lucio
Yang, James C. H.
Dingemans, Anne-Marie
Kim, Dong-Wan
de Marinis, Filippo
Schulz, Mathias
Liu, Shiyao
Gupta, Ravindra
Smoljanovic, Vlatka
Ou, Sai-Hong Ignatius
LUNG CANCER-TARGETS AND THERAPY, 2019, 10 : 125 - 130
[3] Pooled Efficacy and Safety Data from Two Phase II Studies (NP28673 and NP28761) of Alectinib in ALK plus Non-Small-Cell Lung Cancer (NSCLC)
Yang, James Chih-Hsin
Ou, Sai-Hong
De Petris, Luigi
Gadgeel, Shirish
Gandhi, Leena
Kim, Dong-Wan
Barlesi, Fabrice
Govindan, Ramaswamy
Dingemans, Anne-Marie
Crino, Lucio
Lena, Herve
Popat, Sanjay
Ahn, Jin Seok
Dansin, Eric
Golding, Sophie
Bordogna, Walter
Balas, Bogdana
Morcos, Peter N.
Zeaiter, Ali
Shaw, Alice
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1170 - S1171
[4] Effect of alectinib on cardiac electrophysiology: results from intensive electrocardiogram monitoring from the pivotal phase II NP28761 and NP28673 studies
Peter N. Morcos
Katrijn Bogman
Stanislas Hubeaux
Carolina Sturm-Pellanda
Thorsten Ruf
Walter Bordogna
Sophie Golding
Ali Zeaiter
Markus Abt
Bogdana Balas
Cancer Chemotherapy and Pharmacology, 2017, 79 : 559 - 568
[5] Effect of alectinib on cardiac electrophysiology: results from intensive electrocardiogram monitoring from the pivotal phase II NP28761 and NP28673 studies
Morcos, Peter N.
Bogman, Katrijn
Hubeaux, Stanislas
Sturm-Pellanda, Carolina
Ruf, Thorsten
Bordogna, Walter
Golding, Sophie
Zeaiter, Ali
Abt, Markus
Balas, Bogdana
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (03) : 559 - 568
[6] Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small cell lung cancer (NSCLC).
Ou, Sai-Hong Ignatius
Gandhi, Leena
Gadgeel, Shirish M.
Barlesi, Fabrice
Yang, James Chih-Hsin
De Petris, Luigi
Kim, Dong-Wan
Govindan, Ramaswamy
Dingemans, Anne-Marie C.
Crino, Lucio
Herve, Lena
Popat, Sanjay
Ahn, Jin Seok
Dansin, Eric
Zeaiter, Ali Hassan
Mueller, Barbara
Johannsdottir, Hrefna
Balas, Bogdana
Morcos, Peter N.
Shaw, Alice
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[7] Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer
Ou, Sai-Hong Ignatius
Gadgeel, Shirish M.
Barlesi, Fabrice
Yang, James Chih-Hsin
De Petris, Luigi
Kim, Dong-Wan
Govindan, Ramaswamy
Dingemans, Anne-Marie
Crino, Lucio
Lena, Herve
Popat, Sanjay
Ahn, Jin Seok
Dansin, Eric
Mitry, Emmanuel
Mueller, Barbara
Bordogna, Walter
Balas, Bogdana
Morcos, Peter N.
Shaw, Alice T.
LUNG CANCER, 2020, 139 : 22 - 27
[8] Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer
Yang, James Chih-Hsin
Ou, Sai-Hong Ignatius
De Petris, Luigi
Gadgeel, Shirish
Gandhi, Leena
Kim, Dong-Wan
Barlesi, Fabrice
Govindan, Ramaswamy
Dingemans, Anne-Marie C.
Crino, Lucio
Lena, Nerve
Popat, Sanjay
Ahn, Jin Seok
Dansin, Eric
Golding, Sophie
Bordogna, Walter
Batas, Bogdana
Morcos, Peter N.
Zeaiter, Ali
Shaw, Alice T.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (10) : 1552 - 1560
[9] Updated Efficacy/Safety Data From the Phase 2 NP28761 Study of Alectinib in ALK plus NSCLC
Shaw, Alice
West, Howard
Socinski, Mark A.
Ou, Ignatius
Gandhi, Leena
Gadgeel, Shirish
Belani, Chandra P.
Shirai, Keisuke
Bazhenova, Lyudmila
Santos, Edgardo
Riely, Gregory J.
Chiappori, Alberto
Cetnar, Jeremy
Mekhail, Tarek
Chao, Bo
Borghaei, Hossein
Gold, Kathryn A.
Johannsdottir, Hrefna
Ruf, Thorsten
Boisserie, Frederic
Henschel, Volkmar
Zeaiter, Ali
Camidge, Ross
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S237 - S238
[10] Updated efficacy and safety from the global phase II NP28673 study of alectinib in patients (pts) with previously treated ALK plus non-small-cell lung cancer (NSCLC)
Barlesi, F.
Dingemans, A-M. C.
Yang, J. C-H.
Ou, S-H. I.
Ahn, J. S.
De Petris, L.
Hughes, B.
Lena, H.
Bordogna, W.
Golding, S.
Morcos, P. N.
Balas, B.
Zeaiter, A.
Kim, D-W.
ANNALS OF ONCOLOGY, 2016, 27

← 1 2 3 4 5 →